TL;DR
A phase II trial of a bioerodible implant releasing kamuvudine K8 found that the mid-level dose reduced geographic atrophy lesion growth rate by 54% over six months under the study’s preferred model. The trial was small and short, and it was not designed to establish a benefit in vision; a larger, longer study is planned.
In a 30-patient phase II trial, a bioerodible implant releasing kamuvudine K8 was associated with a 54% reduction in geographic atrophy lesion growth rate over six months at the mid-level dose, researchers reported October 14 at the American Academy of Ophthalmology meeting. The preliminary result points to a different approach from currently approved treatments, but the study was small and was not designed to show whether the implant preserves vision.
Get oils, diffusers and self-care delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
The trial enrolled people with geographic atrophy (GA) in both eyes. Ten participants received each of three K8 dose levels in the eye with worse vision; the other eye served as a control. The primary measure was the rate of lesion growth at six months. Control-eye lesions grew by an average of 1.18 square millimeters during that period.
For the mid-level dose, the growth-rate reduction was 54% using the FDA-preferred slope model (P=0.016), and 50% compared with control after adjustment for initial lesion size (P=0.005). The reported effect increased over time: the best-performing dose showed a 43% reduction during the first three months and a 70% reduction during months three through six. Across dose groups, the mid- and high-dose results were statistically significant against pooled control eyes; the low dose did not show a difference from control.
Researchers also reported that 25 of 30 patients had slower GA growth in the treated eye than in the fellow eye. A prespecified visual-acuity analysis found a four-letter difference favoring treated eyes among 14 treated and 16 control eyes (P=0.004). However, investigators said the trial was not powered to assess visual acuity, and vision was not masked. No drug-related adverse events were reported during the study.
A Different Target for GA Treatment
GA is an advanced form of age-related macular degeneration that damages retinal tissue and can impair central vision. The reported result matters because K8 is designed to act on inflammation pathways, rather than the complement pathway targeted by the two approved GA treatments described in the report. K8 inhibits activation of the NLRP3 and NLRC4 inflammasomes, which researchers said contribute to retinal pigment epithelium degeneration in preclinical models.
The findings offer an early signal that a sustained-release implant using this mechanism may slow the enlargement of GA lesions. That is not the same as proof that patients see better or retain vision for longer. The distinction is important for patients weighing treatment options: the study measured lesion growth over six months, while a larger trial will need to test whether any anatomical effect translates into a meaningful visual benefit and whether it persists over time.
Products Worth Considering
Fitbit Charge 5 Health and Fitness Tracker with Built-In GPS, Stress Management, Sleep Tracking, and 24/7 Heart Rate Monitoring
Withings Sleep Under-Mattress Sleep Tracking Pad
BowFlex Results Series SelectTech Adjustable Dumbbells, Pair
As an affiliate, we earn on qualifying purchases.
How the K8 Trial Was Structured
K8 is a bioerodible implant that continually releases the drug. At the meeting, lead investigator Liangbo Shen of Duke University Medical Center described it as a quarterly injection that does not require refrigeration and comes in a preloaded injector. Those are proposed practical advantages, not outcomes established by the lesion-growth analysis.
The study compared the treated eye with the fellow eye in participants who had bilateral GA and had not previously received GA treatment. Eligibility included lesion areas of 2.5 to 20 square millimeters, specified retinal imaging findings, and a minimum level of visual acuity; people with a history of exudative age-related macular degeneration were excluded. The six-month follow-up and small dose groups limit what can be concluded about long-term effects and dose differences.
Shen said the drug retains anti-inflammatory activity associated with its class but lacks antiviral activity and related mitochondrial toxicity. That is the investigator’s description of the drug’s properties; the trial report does not establish long-term safety from this short follow-up. The result remains an early clinical finding rather than evidence that K8 is an approved or established treatment.
“We need a longer, larger study to investigate the treatment efficacy.”
— Liangbo Shen, MD, Duke University Medical Center
Vision Benefit and Long-Term Effects
The study does not establish that K8 improves or preserves vision. The visual-acuity comparison was not a primary, adequately powered test, and Stewart noted that participants’ vision was not masked. Shen also acknowledged that researchers treated the eye with more severe GA, which could affect interpretation. The reported four-letter difference should therefore be treated as an exploratory finding rather than evidence of a confirmed functional benefit.
Questions also remain about dose response and how robust the lesion-growth result is. Investigators pooled control-eye results, a choice Stewart said could make the analysis sensitive to outliers. Shen said a comparison of treated and untreated eyes within the same participants produced similar results after adjustment for sample size and other factors. Still, six months may be too short to identify a true dose effect: the low dose did not differ from control, and the mid- and high-dose groups did not differ significantly from each other. The small sample also cannot rule out uncommon or later adverse effects.
Larger Trials Will Test K8
Shen said a phase III pivotal clinical program is planned. The source report did not give a start date, trial size, full study design, or expected readout, so those milestones remain unknown. A larger and longer study will need to test whether the reduction in lesion growth can be repeated across participants and whether it is accompanied by a measurable benefit in visual function.
Until those results are available, the phase II findings should be read as preliminary. Researchers will also need to clarify the comparative performance of the doses and assess safety over longer follow-up. K8’s convenience features and proposed inflammatory mechanism may be relevant to future treatment choices, but they do not establish clinical advantage over existing options.
Key Questions
What did the phase II trial find?
The mid-level K8 dose was associated with a 54% reduction in GA lesion growth rate over six months using the FDA-preferred slope model. It was a small study of 30 patients, and the result needs confirmation.
Does the result mean K8 improves vision?
No. The study was not powered to assess visual acuity. Researchers reported a four-letter difference favoring treated eyes in an analysis, but masking and study-size limitations mean that finding does not establish a vision benefit.
How does K8 differ from approved GA treatments?
The report describes approved treatments as complement inhibitors. K8 is a nucleoside reverse transcriptase inhibitor intended to block the NLRP3 and NLRC4 inflammasomes, two inflammation-related pathways.
Were drug-related adverse events reported?
Researchers reported no drug-related adverse events at any dose during the six-month trial. The small sample and short follow-up cannot establish long-term safety or rule out uncommon effects.
What happens next?
Investigator Liangbo Shen said a phase III pivotal program is planned. Details such as its launch date, size and expected results were not provided in the source report.
Source: rss
